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The empirical hypothesis generation and testing approach to pharmaceutical research
and development (R&D), and biomedical research has proven very effective over the last
half-century; resulting in tremendous increases productivity and the rates of approval for
new drug applications at the Food and Drug Administration (FDA). However, as discovery
of new therapeutic approaches for diseases with unmet medical need becomes more
challenging, the productivity and efficiency of the traditional approach to drug discovery
and development is diminishing. Innovative approaches are needed, such as those offered
by Quantitative Systems Pharmacology (QSP) modeling and simulation. This “systems”
approach to modeling and simulation can be used to guide the hypothesis generation
and testing process in pharmaceutical R&D, in a manner similar to its adoption in other
industries in the past. Embedding QSP into the existing processes within pharmaceutical
discovery and development will be required in order to realize the full beneficial impact of
this innovative approach.
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INTRODUCTION
One of the oldest documents recording the process of drug
discovery is the Ancient Egyptian “materia medica” dating to the
sixteenth century B.C. This approach to drug discovery, based on
empirical evidence from the natural world, is known as Pharma-
cognosy (de Pasquale, 1984), and was the primary means of drug
discovery until the middle of the twentieth century. Advances
in biochemistry, molecular and cellular biology, and medicinal
chemistry during middle of the twentieth century resulted in a
shift to a more hypothesis driven, mechanism-based approach
to drug discovery (Drews, 2000). This approach includes mining
of data from human epidemiology studies, combined with non-
clinical in vitro and in vivo experiments to demonstrate the
validity of a therapeutic target. The addition of high through-
put chemical synthesis and screening permits identification of
target selective, high affinity compounds. This hypothesis driven
approach to pharmaceutical research and development (R&D)
has been a tremendous advance relative to the ancient methods
of Pharmacognosy, and resulted in a dramatic increase in the per-
centage of new drug applications (NDAs) approved by the Food
and Drug Administration (FDA) since the early 1960s (Figure 1A;
U.S. Food and Drug Administration, 2013b). However, there
appears to be a decrease in the productivity (Figure 1B) of this
approach that appears to be due to at least two major factors.
One being the increasing difficulty in finding novel therapeu-
tic targets, either for diseases with well established standards
of care or those with unmet medical need (Pammolli et al.,
2011; Scannell et al., 2012), and the other being the increasing
cost associated with discovery and drug development of new
drugs. The current average cost to bring a drug to market is
$1.5 billion, over 10 times higher than the cost in the 1970s
(DiMasi and Grabowski, 2007; Scannell et al., 2012). The need for
improved productivity in the pharmaceutical industry has been
recognized by the FDA, with the establishment of its “Critical
Path Initiative” in 2004. This initiative was intended to improve
the drug and medical device development processes, the quality
of evidence generated during development, as well as the out-
comes of clinical use of these products (Woodcock and Woosley,
2008).
COMPUTER MODELING AND SIMULATION AS TOOLS TO
IMPROVE PRODUCTIVITY
A decline in productivity is to be expected for any industry
as it matures, and the competition from established products
increases. This decline in productivity is typically associated
with increasing development costs, partly due to the difficulty
in differentiating one product from another in the marketplace.
Industries must find innovative ways to increase the probability
of commercial success while at the same time decreasing devel-
opment costs. Most industries eventually realize the value of
computer aided modeling and simulation as one of the means
for achieving both of these objectives. Computer aided modeling
and simulation allows testing of numerous potential scenarios
“in silico” to eliminate those associated with a low probability of
success, avoiding the tremendous costs of evaluating all of those
failed scenarios in the real world. Today, aerospace, automotive,
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FIGURE 1 | (A) Rate of approval for NDAs since 1960 (U.S. Food and Drug Administration, 2013b). (B) Number of approved drugs for every billion US dollars
spent on R&D (adjusted for inflation; Scannell et al., 2012).
electronics, and other industries routinely incorporate modeling
and simulation into their R&D processes (Woltosz, 2012). The
pharmaceutical industry has been slow to integrate computer
aided modeling and simulation for many reasons: including the
perception that biology and pharmacology are “too complex”
to be modeled with mathematical equations; a lack of adequate
graduate training programs for pharmaceutical modeling and
simulation scientists; and the lack of support from government
funding agencies for academic research in computer aided mod-
eling and simulation approaches for biomedical research. How-
ever, in the last decade, both the FDA and National Institutes
of Health (NIH) have recognized the value of modeling and
simulation in increasing productivity in biomedical research and
pharmaceutical R&D. The FDA established its Pharmacometrics
Division in 2009 to promote and evaluate the use of modeling and
simulation approaches in regulatory submissions to the agency
(U.S. Food and Drug Administration, 2013a). In 2011, the NIH
published a white paper describing the emerging discipline of
Quantitative Systems Pharmacology (QSP) modeling, and rec-
ommended the establishment of NIH-supported interdisciplinary
research and training programs for QSP (Sorger et al., 2011).
QSP modeling and simulation is a new term to describe the
integration of two disciplines that have been increasingly useful in
biomedical research and pharmaceutical R&D; “Systems Biology”
and “Quantitative Pharmacology.” Systems Biology is the field of
biomedical research that seeks to characterize biological networks
of interactions, including those between genes and biologically
active molecules to develop models of these systems that are
usually qualitative in nature. Quantitative Pharmacology (a.k.a.
Pharmacometrics) is the field of biomedical research that seeks
to use computer aided modeling and simulation to increase our
understanding of the pharmacokinetics (PK) and pharmacody-
namics (PD) of drugs, and to aid in the design of pre-clinical and
clinical experiments. The purpose of QSP modeling is to develop
quantitative computer models of biological systems and disease
processes; as well as the effects of drug PK and PD on those
systems.
PHARMACEUTICAL R&D AND QUANTITATIVE SYSTEMS
PHARMACOLOGY
Pharmaceutical R&D is a stepwise process where investment in
further characterizing the pharmacology of a candidate molecule
is incrementally increased as confidence in the molecule’s proba-
bility of regulatory and commercial success increases. Investment
initially starts with in vitro biochemical and pharmacology stud-
ies; then moves to animal pharmacology and toxicology studies,
then to human healthy volunteer pharmacology and toxicol-
ogy studies; and finally to large and expensive patient efficacy
and safety studies. QSP models are based on the fundamental
understanding of biological pathways, disease processes, and drug
mechanisms of action. Therefore, they are very effective tools for
integration of prior collected biological/pharmacological knowl-
edge, formulation of pharmacological hypotheses, and for effi-
cient translation between the various experimental models within
pharmaceutical R&D. Key milestones in R&D where QSP models
will be critical to increasing the probability of success will be in the
target identification stage, the transition from pre-clinical to first
in man studies, the transition from healthy volunteer to patient
studies, and the transition from adult to pediatric (Figure 2A).
These milestones represent the point where knowledge from one
set of experimental models (e.g., animal) must be effectively
translated to another set (e.g., human). QSP can facilitate this
translation by formal integration of the knowledge from the
original experimental model and generation of hypotheses for
potential outcomes in the next experimental model. Computer
aided simulations to guide the design of experiments intended to
test those hypotheses.
In addition to their utility in translation between experimental
models, QSP allows prediction of the effects of multiple ther-
apeutic interventions in combination. As it becomes clear in
many therapeutic areas that modulation of single drug targets is
less effective (e.g., oncology, virology), the cost of testing all of
the potential combinations in the clinic is prohibitive. QSP can
provide a framework in which to evaluate these potential combi-
nations prior to testing in the clinic, by providing a fundamental
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FIGURE 2 | Continued
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FIGURE 2 | Continued
(A) Incorporation of Quantitative Systems Pharmacology modeling and
simulation in pharmaceutical R&D. Drug discovery and development is a
long and complex process with numerous transition periods where
effective translation from one experimental model to the next is a
challenge. Major transitions occur when moving to first in man studies
and first in pediatric studies. The cycles of application of QSP modeling
and simulation are defined by (1) integration of experimental data and
biological knowledge to develop QSP models; (2) generation of
hypotheses for potential outcomes in future experiments; (3) testing of
those hypotheses with experiments that have been designed via
simulation from QSP models. (B) Integration of QSP models in
pharmaceutical R&D process. The model development team should be a
sub-team of existing drug discovery and development teams. The goals
of the model development team are to develop QSP models for their
particular disease area and/or to apply existing QSP models to facilitate
key milestones in discovery and development. The model development
process should be rigorous and stepwise, so that models that are
developed can used broadly in the disease area and can be used to
communicate with regulatory agencies.
systems and quantitative understanding of how these different
mechanisms will interact.
PHARMACEUTICAL R&D AND QUANTITATIVE SYSTEMS
PHARMACOLOGY
Published examples describing the use of QSP modeling and sim-
ulation to facilitate biomedical research and pharmaceutical R&D
have been increasing in recent years. Most of these publications
have been focused on PK, since the processes that govern drug
absorption, distribution, metabolism, and excretion are better
established compared to those that govern disease biology and
PD (Edginton et al., 2008). Strougo et al. (2012) demonstrated
the use of these physiologically based PK (PBPK) models for
prediction of PK in children prior to the conduct of the first
pediatric clinical studies. There are software packages that can be
licensed with PBPK models incorporated that allow prediction of
in vivo drug PK based on the in vitro properties of the molecule
(Kuentz et al., 2006; Jamei et al., 2009). QSP models that predict
both PK and PD are much more complex, and tend to be disease
area specific. Vega-Villa et al. (2013) published a QSP model of
the nitric oxide metabolic pathways and demonstrated the models
ability to predict toxic methemoglobin levels in humans treated
with nitric oxide. Geerts et al. (2013a) published a QSP model
of cognitive deficit in schizophrenia and were able to simulate
the enhancement of cognition with clozapine and risperidone,
as well as the worsening of cognition with γ -aminobutyric acid
(GABA) modulators lorazepam and flumazenil. There are soft-
ware packages that can be licensed that allow prediction of both
PK and PD for a variety of drugs and mechanisms of action, but
at much greater expense compared with those used for PBPK
alone (Shoda et al., 2010; Eissing et al., 2011). Agoram and Demin
(2011) reported on the development and application of a QSP
model of the PD of the 5-lipoxygenase (5-LO) pathway. This QSP
model has been used to explain the complex PK–PD relationship
of zileuton, a marketed 5-LO inhibitor (Karelina et al., 2010).
The model was able to demonstrate the mechanism behind the
longer duration, but similar magnitude, of action with the 600
vs. 400 mg dose of zileuton. More important for its utility in
drug discovery, this QSP model could be used to predict the
PK and PD of a new molecule or combination of molecules
intended to modulate another component of the 5-LO pathway
based solely on the biophysical properties of the molecule and
its potency at the target. One could then design a series of in
vivo experiments to validate the hypotheses generated from these
predictions.
Quantitative Systems Pharmacology holds great promise
in being able to uncover innovative therapeutic paradigms
for complex multi-factorial diseases such as Alzheimer’s and
diabetes. Because these diseases involve multiple physiologi-
cal processes and can affect multiple organs, QSP can pro-
vide an integrated understanding of the pathology as well as
the possible complex counter-intuitive results of therapeutic
intervention.
INTEGRATION OF QUANTITATIVE SYSTEMS
PHARMACOLOGY INTO PHARMACEUTICAL R&D
In order to leverage QSP to accomplish this, it must be properly
integrated into the decision making process in pharmaceutical
R&D. As mentioned above, it is possible to license PBPK and
QSP models to facilitate decision making in pharmaceutical
discovery and development. However, since licensing is often
limited to a few specialized functions, this approach decreases
the flexibility and utility of QSP across the different functions
within R&D. QSP models should be integrated into the processes
of discovery and development within pharmaceutical compa-
nies in order to maximize their potential benefit on R&D effi-
ciency and productivity. To better integrate these models into
the existing processes, they can be developed internally within
the drug discovery and development teams. In addition, the
teams must be organized and educated to support this inte-
gration. Figure 2B shows the integration of the QSP model
development team with the drug discovery and development
team. Development of a QSP model for prediction of clinical PK
and PD should be a rigorous and stepwise process, with three
main steps:
(1) Model Scope: Development of the scope of the model, with
delivery of a physiological pathway map representing all of
the biological/pharmacological processes that will be incor-
porated in the model;
(2) Model Development: Prior models, relevant non-clinical and
clinical data are collected to inform the incorporation of
the mathematical equations that describe the processes and
compartment volumes in the model;
(3) Model Qualification: The model is calibrated to relevant data
from the target patient populations.
In addition to the modeling engineer, who will incorporate
the equations into the model based on the agreed upon scope,
critical individuals on the model development team include the
following:
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• Biologist and Clinician: Guide the scope of the model and
inform the integration of relevant biology/pharmacology into
the model, as well as identifying non-clinical and clinical data
to be used in model development and qualification;
• Data Programmer: Curates and maintains the clinical/non-
clinical databases that serve as inputs to the model;
• Statistician: Guide analysis of the simulation outputs and how
they are used to inform the design of future clinical trials; the
modeling engineer will incorporate the mathematical equa-
tions in the model and calibrate the model to relevant clinical
data;
• Information Technologist: Maintain the software interface to
the model and develop software for simulation;
• PK/PD Scientist: Provide broad expertise on the PK and PD
aspects of the model and will serve as the primary mediator
between the model development team and drug discovery and
development team.
Once a QSP model is developed, it should be regularly updated
with relevant internal and external research. In addition, it should
be made available to all scientists in R&D that work in that
particular disease area. The QSP model can be made flexible such
that it can be readily adapted to other species that may be of
interest in drug discovery (e.g., rat, monkey, rabbit, etc.). This
would facilitate translation of experiments between these species
and human.
OUTLOOK FOR QUANTITATIVE SYSTEMS PHARMACOLOGY
IN PHARMACEUTICAL R&D
Quantitative Systems Pharmacology holds great promise in being
able to uncover innovative therapeutic paradigms for complex
multi-factorial diseases such as Alzheimer’s and multiple sclerosis.
Because these diseases involve multiple physiological processes
and can affect multiple organs, QSP can provide an integrated
understanding of the pathology as well as the possible complex
results of therapeutic intervention. QSP thus offers pharmaceu-
tical R&D an innovative way to conduct at drug discovery and
development, particularly in diseases that are poorly translated
from animal disease models. Geerts et al. (2013b) recently pub-
lished an article on how QSP, when combined with pheno-
typic screening and preclinical animal models, could be used to
address the bottleneck in both cognitive and neuropsychiatric
drug discovery and development for Alzheimer’s disease. For such
complex diseases that are poorly translated from animal disease
models, target-focused drug discovery holds little promise for
finding successful therapies. However, pharmaceutical companies
are large and bureaucratic, and dramatic changes to the direction
in which R&D is conducted may be adopted rather slowly.
There are smaller pharmaceutical and biotech companies that
are fully integrating QSP into their biomedical R&D processes.
One example is Merrimack Pharmaceuticals in Cambridge, MA,
USA; founded by MIT professor of Biology and Biological Engi-
neering Michael Yaffe. Merrimack states on their website, “We
are a Systems Biology company. We believe that improving can-
cer care requires a systems-based understanding of the dynamic
interactions within a cancer cell and its environment” (Merrimack
Pharmaceuticals Inc., 2014). The scientific and financial com-
munities will be watching these small companies, and if their
model for a systems-based approach to R&D is successful, the
pressure will be increased for “large pharma” to more fully adopt
such innovative approaches into their discovery and development
processes.
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